Reference Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach
No data available in table

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role
No data available in table

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
No data available in table

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
No data available in table

Filter rows:

Showing 0 to 0 of 0 entries

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance
No data available in table

Filter rows:

Showing 1 to 34 of 34 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + GSK2636771 + unspecified IGF-1R antibody	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + GSK2636771	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + unspecified IGF-1R antibody	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + Encorafenib + GSK2636771	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + AZD6482 + Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Mektovi (binimetinib), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	Binimetinib + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Mektovi (binimetinib) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + Encorafenib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Mektovi (binimetinib), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Encorafenib	Preclinical	Actionable	In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	Pictilisib	Preclinical	Actionable	In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	no benefit	Alpelisib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	Binimetinib + GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 and Mektovi (binimetinib) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Mektovi (binimetinib), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	NVP-AEW541 + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib	Preclinical	Actionable	In a preclinical study, AZD6482 and Mektovi (binimetinib) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	TGX-221	Preclinical	Actionable	In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + AZD6482 + Encorafenib	Preclinical	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + AZD6482 + Binimetinib + Encorafenib	Preclinical	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Mektovi (binimetinib), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Encorafenib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + unspecified IGF-1R antibody	Preclinical	Actionable	In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	no benefit	Alpelisib + Encorafenib	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482	Preclinical	Actionable	In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	no benefit	Alpelisib + Binimetinib	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and Mektovi (binimetinib) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN inact mut	melanoma	decreased response	Alpelisib	Preclinical	Actionable	In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).	26577700
BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + Binimetinib	Preclinical	Actionable	In a preclinical study, AZD6482 and Mektovi (binimetinib) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN wild-type	melanoma	no benefit	GSK2636771 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN wild-type	melanoma	no benefit	Encorafenib + GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + Encorafenib	Preclinical	Actionable	In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
BRAF mut PTEN wild-type	melanoma	no benefit	Binimetinib + GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 and Mektovi (binimetinib) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700

Showing 1 to 34 of 34 entries

Filter rows:

Reference Detail

Contact

Filtering

Sorting